Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

NAICS 2022 code 541715 — a Histometrics industry primer

1. Overview

This industry is the business of doing research and experimental development as a paid service — for someone else. Its establishments are laboratories, engineering-research shops, and contract research organizations (CROs — firms hired to run drug and device trials and the lab studies behind them) that get paid to invent, test, and de-risk products across the physical sciences (chemistry, physics, materials, energy), engineering (aerospace, electronics, nuclear, robotics), and the non-biotech life sciences (medicine, pharmacy, agriculture, environment). It deliberately excludes the two most-hyped R&D niches — nanotechnology and biotechnology — which have their own codes.[1]

The right way to see it is a contract-driven, high-skill services market, not a single corporate sector. When a drug company, a defense agency, an energy department, or an automaker decides to develop something new but does not want to build and staff the lab itself, this industry gets the contract. It is labor-heavy, high-wage, and increasingly outsourced — a structural tailwind.

There is no clean public-market proxy for the whole code. Both drafts of this primer's underlying research agree: most listed operators mix 541715-type work with consulting, IT, engineering, diagnostics, manufacturing, or government program operations. Two doors exist:

• Public-market route: a small set of pure-play CROs and lab-services firms (IQVIA, ICON, Charles River, Medpace, Fortrea, Inotiv), plus federal science-and-engineering contractors that carry government-R&D exposure inside larger service businesses (Leidos, SAIC, Amentum, Parsons, KBR, Jacobs, Exponent).
• Private route: heavy private-equity (PE) ownership of the mid-tier CROs, private government-tech platforms (Peraton), plus large non-profit research institutes (Battelle, SRI International, Southwest Research Institute, RTI, MITRE) that dominate government science but cannot be bought at any price.

2. What it is and how it's structured

Code 541715 covers establishments primarily engaged in conducting R&D in fields such as agriculture, electronics, environment, biology, computers, chemistry, food, geology, health, mathematics, medicine, oceanography, pharmacy, physics, robotics, and veterinary science.[1] The defining feature is that R&D is the establishment's main line of business — not an in-house cost center. Prototype production is excluded; this is research, not manufacturing.[1]

Typical work spans basic and applied research; engineering design, modeling, prototyping, and simulation; energy, nuclear, space, defense, materials, environmental, agricultural, and medical research; and contract studies for government agencies, industrial and pharmaceutical companies, universities, and foundations.

What it excludes (and where that work lands instead):

• Nanotechnology R&D → NAICS 541713.[1]
• Biotechnology R&D → NAICS 541714. This matters: much modern drug discovery is "biotech," so a large slice of pharma research sits next door, not here — and even a clinical CRO's book of work straddles the 541714/541715 line.[1]
• Social-science and humanities R&D → NAICS 541720.[1]
• Testing laboratories (541380), engineering services (541330), industrial design (541420), and medical laboratories (621511) — routine testing, applied engineering, and diagnostics are not experimental R&D.[1]
• In-house corporate R&D → classified with the parent's industry (a carmaker's R&D lab counts as auto manufacturing, not here). This is the single most important scope point — see Section 3.
• University research → classified under higher education, even though it is enormous.

Ownership mix. Three very different owner types share this one code, and the federal data does not split them out:

1. For-profit contract research firms — the CROs, commercial labs, and engineering-research shops, from global public companies to thousands of small specialists.
2. Non-profit research institutes — Battelle, SRI International, Southwest Research Institute (SwRI), RTI International, MITRE — large, tax-exempt, and not investable.[9][10][11]
3. Contractor-run federal labs (FFRDCs) — federally funded research and development centers such as the national laboratories, operated for the government by companies, universities, or non-profits.[8]

3. How big it is

Our ground-truth federal figures for NAICS 541715. They come from different federal series and years, so treat them as a set of readings, not one continuous market estimate:

Two things stand out. First, this is a high-wage industry: $88.2 billion of payroll across 596,332 workers is roughly $148,000 per employee — scientists, engineers, statisticians, and clinical-research staff, not minimum-wage labor.[3] Second, the average firm is mid-sized: about $18.6 million of revenue and ~46 employees per establishment.[2][3]

The undercount caveat — this is critical. The $195.7 billion here is only R&D sold as a service. It is a small fraction of all R&D performed in the United States. Total U.S. R&D reached $937 billion in 2023 (with 2024 estimated at $993 billion), of which businesses performed $722 billion — but the vast majority of that is in-house R&D booked inside pharma, tech, aerospace, energy, and auto companies and classified under their industries, not here.[5][6] University research (~$108 billion) sits under education.[5] So do not read $195.7 billion as "how much R&D America does." Read it as "the market for R&D you can hire someone else to do" — the outsourced slice. The activity called "R&D" is roughly five times larger than this industry code.

Two further wrinkles. County Business Patterns covers only establishments with paid employees and excludes public administration and most government employees, so government laboratories, university research classified elsewhere, and tiny no-payroll operators are under-counted.[3] And a meaningful chunk of the industry's receipts are federal contract dollars flowing to contractor-run labs and R&D subcontractors, so the total blends private commercial demand with government-funded science.[8]

4. The investable universe

These are operating proxies, not exact NAICS matches. NAICS is assigned to establishments, and government contracts carry their own contracting NAICS code, so no listed company's full revenue maps cleanly to 541715. The public exposure falls into two very different clusters, plus a set of larger platforms.

A. Life-sciences contract research (CROs and lab services). The cleanest listed exposure to R&D outsourcing, though its work straddles the code's biotechnology boundary:

B. Federal science, engineering, and technical-services contractors. These capture the physical-sciences and engineering half of the code — energy, nuclear, space, defense, and materials R&D delivered under government contracts:

C. Broader platforms whose contract-research or lab businesses are material but embedded in much larger enterprises: Thermo Fisher Scientific (TMO), which owns clinical CRO PPD inside a ~$44B-revenue tools company;[17] and Labcorp (LH), whose diagnostics dwarf its remaining research operations.[22]

Major private and non-investable owners:

• Private-equity-owned CROs: Parexel (EQT / Goldman Sachs), Syneos Health (taken private in 2023 for ~$7.1 billion by Elliott, Patient Square, and Veritas).[18][19] Much of the mid-tier is PE-held.
• Private government-tech platforms: Peraton (Veritas Capital-backed).[20]
• Chinese CROs/CDMOs: WuXi AppTec and Pharmaron — large global players now constrained in the U.S. market (Section 7).[29]
• Non-profit research institutes (cannot be bought): Battelle (independent applied-science institute that also operates national labs), SwRI, SRI International, RTI International, MITRE, RAND. Strategically central as competitors and as operators of federal science, but not ordinary equity.[9][10][11]

Bottom line: for direct equity exposure, the clinical-CRO complex is the cleanest life-sciences route and the federal-services names are the cleanest physical-sciences/engineering route — but neither is a pure play on the code, and the non-profits are unbuyable.

5. How the money works

This is a people-and-projects business: the economics revolve around selling technical staff time and running projects to a budget. Two distinct revenue models coexist.

Commercial contract research (the CRO model). Full-service CROs sell multi-year contracts and recognize revenue as work is delivered. The metrics that matter:

• Net new business awards (bookings) — new contracts signed, minus cancellations.
• Backlog — signed-but-not-yet-delivered work. The majors carry huge backlogs (IQVIA ~$31 billion, ICON ~$24.7 billion at recent year-ends), versus far smaller books at mid-caps.[12][13][15] Backlog is the forward revenue engine, but it is cancellable — a sponsor can kill a trial.
• Book-to-bill ratio — bookings ÷ revenue; above 1.0 means the order book is growing (the majors run ~1.0–1.2).[13][15]
• Pricing is either FTE-based (full-time-equivalent staff sold at a rate) or fee-for-service / per-unit (per patient enrolled, per site activated). A large line item is pass-through costs (investigator payments, patient travel) that flow through revenue at little or no margin, so analysts watch net service revenue (fee revenue excluding pass-throughs) for the real trend.

Federal contract research (the government model). Physical-sciences, engineering, and FFRDC work runs on cost-reimbursement, cost-plus-fixed-fee, fixed-price, time-and-materials, and incentive contracts. Cost-reimbursement is common when requirements and costs cannot be estimated precisely; fixed-price transfers overrun risk to the contractor.[23] Profit is thin and steady, and the main risk is losing the contract at recompete. Grants, cooperative agreements, and IP licensing/royalties/milestone payments round out the mix, especially for non-profits and IP-owning labs.

Where profit comes from. The cost base is overwhelmingly salaries for scientists, engineers, technicians, clinical-research associates (CRAs), and compliance staff. Margin is driven by billable utilization (keeping staff on paid work), project execution (finishing on budget), indirect-cost recovery, and avoiding costly re-work or quality failures. Best-in-class operators earn strong margins — Medpace posted a ~17.8% net income margin in 2025.[15]

Sub-model note. Preclinical / lab-model CROs (Charles River) are more capital-intensive — animal-research models, testing facilities — so facility utilization and biotech demand cycles hit them harder than the asset-light clinical CROs.[14] Non-profits reinvest any surplus rather than pay shareholders.[9] Useful company-level tells across both models: revenue per technical employee, funded backlog and recompete win rates, revenue/margin by contract type, labor-cost inflation, customer concentration, cash conversion, and IP economics.

6. What drives demand

Life-sciences side:

• Biopharma R&D budgets and the drug pipeline. Most CRO demand ultimately comes from pharma and biotech development spending; more molecules in development means more trials to run.[30]
• Outsourcing penetration — the secular tailwind. Sponsors keep shifting work from in-house to CROs; industry estimates put large-pharma outsourcing of development at roughly 45% and rising as companies favor asset-light models.[30]
• Biotech funding cycles. Small and mid-cap biotechs fund trials with venture capital and equity raises, which are interest-rate-sensitive — the industry's main cyclical swing factor. Cheap funding starts trials; higher rates bring cancellations and delays.[30]
• Trial complexity (oncology, rare disease, cell/gene therapy) and new modalities (GLP-1 drugs, AI-designed molecules) raise the value per trial and push work toward specialists.[30]

Physical-sciences and government side:

• Federal science and technology budgets are the dominant cyclical driver. In fiscal 2024, five agencies — the Department of Defense (DoD), Health and Human Services (HHS), the Department of Energy (DOE), the National Aeronautics and Space Administration (NASA), and the National Science Foundation (NSF) — accounted for 93% of federal R&D obligations, about $181.4 billion.[7]
• Thematic demand: defense modernization, space, cyber, autonomy, and advanced weapons; nuclear and clean energy, critical minerals, and energy resilience; artificial intelligence, advanced computing, semiconductors, batteries, and materials; climate resilience, environmental remediation, agriculture, and infrastructure.

The through-line for both sides is corporate and government outsourcing of specialized research that is expensive or slow to build internally. The outlook is structurally supported but uneven — appropriations and private R&D budgets can shift sharply by agency, administration, product cycle, or financing environment.

7. Regulation

Two regulatory worlds apply, depending on the segment.

Clinical and nonclinical life-sciences work is among the most heavily regulated service activity in the country:

• Good Clinical Practice (GCP) — the FDA's core rules for human trials live in 21 CFR Parts 50 (human-subject protection), 56 (institutional review boards), 312 (investigational new drugs), and 812 (investigational devices), aligned with the international ICH E6 guideline.[26] CROs must be qualified and inspectable; the FDA can issue Form 483 observations or warning letters for lapses.
• The Common Rule (45 CFR Part 46) governs federally supported research involving human subjects, requiring informed consent and Institutional Review Board (IRB) protections.[25]
• Good Laboratory Practice (GLP) — 21 CFR Part 58 governs nonclinical safety studies supporting regulated products.[26]
• Animal research — the Animal Welfare Act, institutional animal-care committees (IACUCs), and USDA oversight govern preclinical model work (central to Charles River).
• Data integrity and privacy — electronic records must meet 21 CFR Part 11; patient data is subject to HIPAA.

Federal, physical-sciences, and engineering work carries a different stack:

• Federal procurement: the Federal Acquisition Regulation (FAR), especially Part 35 (R&D contracting) and Subpart 16.3 (cost-reimbursement), governs contract type, allowable costs, audits, subcontracting, and IP provisions.[23]
• Export controls: the International Traffic in Arms Regulations (ITAR) and Export Administration Regulations (EAR) can restrict technical data and foreign-person access; the EAR's fundamental-research exception generally hinges on the ability to publish results broadly.[24]
• IP and technology transfer: the Bayh-Dole framework lets contractors and non-profits retain rights to inventions from federally funded R&D while preserving government rights and reporting duties.[27]
• Small-business contracting: the SBA size standard for 541715 is 1,000 employees; affiliates generally count toward eligibility.[4]

BIOSECURE Act (new). Signed into law in December 2025 as part of the FY2026 defense bill, it restricts federal dealings with named Chinese "biotechnology companies of concern," and the DoD added WuXi AppTec to its Section 1260H list in June 2026.[29] This is reshaping global CRO/CDMO supply chains and is a reshoring tailwind for U.S. (and India-based) providers.

8. Competitive dynamics and consolidation

The industry looks fragmented in aggregate and concentrated in pockets — a classic barbell.

Aggregate: very fragmented. Across all 10,504 firms, the top four hold just 17.7% of receipts, the top eight 25.3%, the top 20 37.5%, the top 50 49.5%, and the Herfindahl-Hirschman Index (HHI, a concentration gauge that runs to 10,000) is only 117 — far below the ~1,500 threshold regulators treat as "concentrated."[2] Thousands of small physical-sciences, engineering, agricultural, and government-R&D shops populate the long tail.

But individual niches are concentrated. Contract sub-markets cluster around firms with security clearances, contract vehicles, specialized facilities, proprietary methods, or trusted customer relationships. Entry barriers scale accordingly: pure scientific consulting is low-capital but reputation- and talent-dependent; regulated labs need validated processes and compliance history; defense and national-security work adds clearance, export-control, and data-security barriers.

The clinical-CRO tier is an oligopoly that has consolidated aggressively as scale, global trial delivery, data platforms, and preferred-provider status with big pharma favor the largest players:

• Thermo Fisher acquired PPD for $17.4 billion (2021).[17]
• ICON acquired PRA Health Sciences for ~$12 billion (2021).[18]
• Syneos Health was taken private for ~$7.1 billion (2023).[19]
• Labcorp spun off its trials unit as Fortrea (2023).[16]

Government-services consolidation is equally active as firms buy scale, cleared talent, and contract vehicles — e.g., Amentum's 2024 merger with Jacobs' Critical Mission Solutions business.[20] Note the DOJ and FTC's 2023 Merger Guidelines direct attention to competition for specialized labor and services, which can make large horizontal combinations harder to clear.[28] Meanwhile BIOSECURE is pushing work away from Chinese providers toward domestic and allied ones.[29]

9. Risks

• Demand cyclicality. Bookings depend on biotech funding (rate-sensitive) and big-pharma budgets; on the government side, on appropriations. Downturns show up as cancellations and slower awards.[30]
• Cancellable backlog. A large trial or program can be scrapped, erasing future revenue overnight.[12]
• Customer concentration and pricing pressure from a shrinking, consolidating pharma client base or dependence on a single agency.
• Talent costs. Wage inflation and turnover among CRAs, cleared scientists, and engineers compress margins in a people business.
• Regulatory/quality failure. An FDA warning letter, data-integrity finding, or export-control violation can jeopardize study validity and reputation.[26]
• Contract-execution risk. Fixed-price overruns, underbidding, weak indirect-cost recovery, or milestone-payment shortfalls on technical failure.[23]
• Government-funding risk. Physical-sciences and FFRDC work is exposed to federal budget swings, appropriations fights, continuing resolutions, and shifting agency priorities.[7]
• Drug-pricing policy. The Inflation Reduction Act's Medicare price negotiations could dampen certain pipeline economics and, downstream, trial demand.
• M&A integration and antitrust scrutiny on both the CRO and government-services sides.[28]
• Geopolitics cuts both ways. BIOSECURE helps U.S. providers but disrupts supply chains and sponsor relationships mid-stream; the globally staffed majors also carry FX and offshore-delivery risk.[29]
• Poor statistical visibility. Federal business data omit much government and no-payroll R&D, so the code understates the true ecosystem.[3]

10. How to invest and the outlook

Public routes — three buckets:

1. Contract R&D / CROs: IQVIA (IQV), ICON (ICLR), Medpace (MEDP), Fortrea (FTRE), Charles River (CRL, more cyclical/preclinical), Inotiv (NOTV) — the cleanest exposure to R&D outsourcing.[12][13][14][15][16][22] These trade on backlog growth, book-to-bill, and margins rather than dividends; most pay little or no dividend and reinvest for growth.
2. Government engineering and technical services: Leidos (LDOS), SAIC, Amentum (AMTM), Parsons (PSN), KBR, Jacobs (J), Exponent (EXPO) — exposure to federal physical-sciences and engineering R&D, valued on funded backlog, recompete win rates, and contract mix.[20][21][22]
3. Broader platforms: Thermo Fisher (TMO, owns PPD) and Labcorp (LH) — diluted, embedded exposure inside much larger enterprises.[17][22] - Funds: there is no pure-play CRO or 541715 ETF; broad health-care, biotech, life-science-tools, and defense-services baskets give diluted exposure.

Private routes:

• Private equity is the dominant owner of the mid-tier (Parexel, Syneos, Peraton, and many specialists), so buyout and secondary funds are the main private door.[18][19][20]
• Non-profits (Battelle, SwRI, SRI, RTI, MITRE, RAND) are not ownable — relevant only as competitors and operators of federal science.[9][10][11]
• Venture capital in R&D-enabling technology — decentralized/virtual trials, AI drug discovery, lab automation — is an adjacent way to back the industry's modernization.

When underwriting any operator, weigh customer concentration, contract quality, labor utilization, compliance systems, IP rights, backlog funding, and cash conversion.

Outlook (forward-looking judgments, not reported facts). The long-term setup is constructive but not smooth. On the life-sciences side, the entry to 2026 looks better than the 2022–2024 trough: clinical CROs reported stabilizing demand and firmer bookings through 2025 as biotech funding thawed, and independent forecasts expect the U.S. CRO market to keep compounding at high-single-digit-plus rates.[30][31] Three forces should support the group — rising outsourcing penetration, BIOSECURE-driven reshoring toward domestic providers, and AI adoption in trial design and site selection. On the physical-sciences side, defense, energy, space, advanced materials, computing, and environmental needs support sustained federal R&D demand, though it is exposed to budget cycles. What could go wrong: a renewed biotech funding freeze if rates stay high, IRA drug-pricing drag, federal R&D budget cuts, and the ever-present risk of a large program cancellation. Treat this as a quality-cyclical industry — structurally advantaged, but geared to the biopharma and government funding cycles. And never mistake the $195.7 billion of 2022 receipts for the total addressable market, or assume any listed company's full revenue belongs to NAICS 541715.

---

Sources

1. U.S. Census Bureau, "NAICS 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)," 2022. https://www.census.gov/naics/?details=541715&input=541715&year=2022
2. U.S. Census Bureau, 2022 Economic Census — concentration statistics for NAICS 541715 (receipts $195.7B; 10,504 firms; CR4 17.7%, CR8 25.3%, CR20 37.5%, CR50 49.5%; HHI 117.2). https://www.census.gov/data/tables/2022/econ/economic-census/naics-sector-54.html
3. U.S. Census Bureau, County Business Patterns 2023 — NAICS 541715 (12,929 establishments; 596,332 employees; $88.2B annual payroll; $25.4B Q1 payroll); coverage notes (excludes public administration/most government employees). https://www.census.gov/programs-surveys/cbp.html
4. U.S. Small Business Administration, "Table of Small Business Size Standards" (NAICS 541715: 1,000 employees), 2023. https://www.sba.gov/document/support-table-size-standards
5. National Center for Science and Engineering Statistics (NSF NCSES), "U.S. R&D Totaled $937 Billion in 2023; 2024 Estimate $993 Billion," 2025. https://ncses.nsf.gov/pubs/nsf26314
6. NSF NCSES, "Business R&D Performance in the United States Increases to $722 Billion in 2023," 2025. https://ncses.nsf.gov/pubs/nsf25353
7. NSF NCSES, "Federal R&D Obligations Increased in FY 2024" (five agencies = 93% / $181.4B), 2026. https://ncses.nsf.gov/pubs/nsf26317
8. The MITRE Corporation, "FFRDCs — A Primer," 2023; and Congressional Research Service R44629. https://www.mitre.org/sites/default/files/2023-02/FFRDCs-A-Primer.pdf
9. Battelle, "Who We Are," 2026. https://www.battelle.org/who-we-are
10. Southwest Research Institute, "What We Do," 2026. https://www.swri.org/what-we-do
11. SRI International, RTI International, and MITRE organizational pages, 2026. https://www.sri.com/about-us/ · https://www.rti.org/about-us · https://www.mitre.org/
12. IQVIA Holdings Inc., SEC filings (FY2024 revenue ~$15.4B; backlog ~$31.1B; book-to-bill), 2024–2026. https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm
13. ICON plc, "ICON Reports Fourth Quarter and Full Year 2024 Results" (revenue ~$8.28B; backlog ~$24.7B; book-to-bill 1.20), 2025. https://www.iconplc.com/news-events/press-releases/icon-reports-fourth-quarter-and-full-year-2024-results
14. Charles River Laboratories, SEC Form 8-K — Q4/FY2024 results (revenue ~$4.05B), 2025. https://www.sec.gov/Archives/edgar/data/1100682/000110068225000009/crl4q24earningsrelease.htm
15. Medpace Holdings, Inc., "Reports Fourth Quarter and Full Year 2025 Results" (revenue ~$2.53B; net margin ~17.8%; book-to-bill ~1.04x), 2026. https://investor.medpace.com/news-releases/news-release-details/medpace-holdings-inc-reports-fourth-quarter-and-full-year-2025/
16. Fortrea Holdings (FTRE) — Labcorp 2023 spin-off; FY2024 revenue ~$2.69B. https://www.sec.gov/Archives/edgar/data/1965040/000162828026012244/ftre-20251231.htm
17. Fierce Biotech, "Thermo Fisher reels in PPD for $17.4B," 2021. https://www.fiercebiotech.com/cro/thermofisher-to-buy-ppd-for-15b-wsj-report
18. IntuitionLabs, "CRO Consolidation: How Mergers Impact Clinical Trials" (ICON–PRA ~$12B; Parexel PE ownership), 2025. https://intuitionlabs.ai/articles/cro-consolidation-clinical-trials-impact
19. Clinical Trials Arena / Nasdaq, on Syneos Health taken private for ~$7.1B, 2023. https://www.clinicaltrialsarena.com/features/cro-consolidation-is-the-clinical-trials-industry-reaching-a-tipping-point/
20. Amentum Holdings, SEC Form 10-K (2024 combination with Jacobs' Critical Mission Solutions; AMTM public); Veritas Capital (Peraton). https://www.sec.gov/Archives/edgar/data/2011286/000162828025053993/amtm-20251003.htm
21. Leidos Holdings, Inc., SEC Form 10-K (DOE, NNSA, and Frederick National Laboratory support), 2025. https://www.sec.gov/Archives/edgar/data/1336920/000133692025000006/ldos-20250103.htm
22. SEC Form 10-K filings, 2025–2026: SAIC, Parsons (PSN), KBR, Exponent (EXPO), Jacobs (J), Inotiv (NOTV), Labcorp (LH). https://www.sec.gov/cgi-bin/browse-edgar
23. Acquisition.gov, "FAR Part 35: Research and Development Contracting" and "Subpart 16.3: Cost-Reimbursement Contracts," 2026. https://www.acquisition.gov/far/part-35
24. Bureau of Industry and Security, "What Is a Deemed Export?"; U.S. Department of State, ITAR. https://www.bis.gov/learn-support/deemed-exports/what-deemed-export
25. U.S. Department of Health and Human Services, "45 CFR 46 (the Common Rule)," 2025. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html
26. U.S. Food and Drug Administration, "Regulations: Good Clinical Practice and Clinical Trials" (21 CFR Parts 50, 56, 312, 812; GLP Part 58; ICH E6) and IRB guidance, 2025. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/regulations-good-clinical-practice-and-clinical-trials
27. National Institutes of Health, "Inventions and Patents" (Bayh-Dole framework), 2026. https://grants.nih.gov/grants/policy/nihgps/html5/section_8/8.2.4_inventions_and_patents.htm
28. U.S. Department of Justice / Federal Trade Commission, "2023 Merger Guidelines," 2023. https://www.justice.gov/atr/2023-merger-guidelines
29. Arnold & Porter, "The BIOSECURE Act Becomes Law in the United States," December 2025; FDA Law Blog, "WuXi AppTec's 1260H Listing Brings the BIOSECURE Act Back to Center Stage," June 2026. https://www.arnoldporter.com/en/perspectives/advisories/2025/12/the-biosecure-act-becomes-law-in-the-united-states
30. Contract Pharma / Clinical Leader, on CRO outsourcing penetration (~45% of large-pharma development) and 2026 industry outlook, 2025–2026. https://www.clinicalleader.com/doc/cro-industry-outlook-the-next-stage-of-clinical-trial-transformation-0001
31. Coherent Market Insights, "U.S. Contract Research Organization (CRO) Market Size," 2026. https://www.coherentmarketinsights.com/market-insight/us-contract-research-organizations-market-3179